Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with sulfasalazine (moderate certainty).
Oral 5‐aminosalicylic acid probably leads to higher exclusion/withdrawal after entry compared with sulfasalazine (moderate certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).
Oral 5‐aminosalicylic acid showed no clear difference in withdrawal due to adverse event compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid showed no clear difference in exclusion/withdrawal after entry compared with placebo (moderate certainty).
Oral 5‐aminosalicylic acid leads to higher failure to maintain clinical or endoscopic remission compared with sulfasalazine (high certainty).
The review found no eligible studies for this question.
Oral 5‐aminosalicylic acid showed no clear difference in adverse event compared with sulfasalazine (moderate certainty).
Probiotics plus 5‐aminosalicylic acid (5‐ASA) (mesalazine) may leads to higher remission compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Apernyl (acetylsalicylic acid pellet) showed no clear difference in presence of dry socket compared with placebo; GRADE not reported.
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes clinical relapse (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).
Probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) showed no clear difference in maintenance of clinical remission (24 to 52 weeks) compared with 5‐ASA (mesalazine) (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether probiotic + 5‐aminosalicylic acid (5‐ASA) (mesalazine) changes withdrawal due to adverse events (12 to 52 weeks) compared with 5‐ASA (mesalazine) (very low certainty).